Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Thai Nakarin Hospital PCL's Debt-to-EBITDA or its related term are showing as below:
BKK:TNH's Debt-to-EBITDA is not ranked *
in the Healthcare Providers & Services industry.
Industry Median: 2.19 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Thai Nakarin Hospital PCL Debt-to-EBITDA Related Terms
Thai Nakarin Hospital PCL Debt-to-EBITDA Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BKK:TNH vs HCA, THC, DVA: Debt-to-EBITDA Comparison
For the Medical Care Facilities subindustry, Thai Nakarin Hospital PCL's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thai Nakarin Hospital PCL Debt-to-EBITDA vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Thai Nakarin Hospital PCL's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Thai Nakarin Hospital PCL's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Apr. 2026) EBITDA data.
Thai Nakarin Hospital PCL (BKK:TNH) has a Debt-to-EBITDA of 0.00 as of Apr. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Thai Nakarin Hospital PCL. According to the industry distribution chart, Thai Nakarin Hospital PCL ranks #999999 out of 480 companies in the Healthcare Providers & Services industry.
Is Thai Nakarin Hospital PCL's Debt-to-EBITDA too high?
Thai Nakarin Hospital PCL's current Debt-to-EBITDA is 0.00. Based on the distribution chart, Thai Nakarin Hospital PCL ranks #999999 out of 480 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Thai Nakarin Hospital PCL has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Thai Nakarin Hospital PCL's Debt-to-EBITDA compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Thai Nakarin Hospital PCL ranks #999999 out of 480 companies for Debt-to-EBITDA. This places Thai Nakarin Hospital PCL in the lower half of its industry. The industry median Debt-to-EBITDA is 2.19. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Healthcare Providers & Services company?
The median Debt-to-EBITDA among Healthcare Providers & Services companies is 2.19, based on 480 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Thai Nakarin Hospital PCL. For the Healthcare Providers & Services industry, the median Debt-to-EBITDA is 2.19 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thai Nakarin Hospital PCL's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thai Nakarin Hospital PCL stock overvalued right now?
Based on GuruFocus' analysis, Thai Nakarin Hospital PCL (BKK:TNH) is currently considered Modestly Undervalued. The stock's GF Value™ is ฿36.29, compared to a current price of ฿28.75 — trading 20.8% below its estimated fair value. The current Debt-to-EBITDA is 0.00. Thai Nakarin Hospital PCL's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Thai Nakarin Hospital PCL (BKK:TNH), the current Debt-to-EBITDA is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thai Nakarin Hospital PCL (BKK:TNH) Overvalued in 2026?
Based on GuruFocus' analysis, Thai Nakarin Hospital PCL stock appears to be undervalued.
The current stock price of ฿28.75 is trading 20.8% below its estimated GF Value™ of ฿36.29.
GuruFocus considers Thai Nakarin Hospital PCL to be Modestly Undervalued.
Key valuation signals for BKK:TNH:
Debt-to-EBITDA: 0.00
GF Value™: ฿36.29 vs. price of ฿28.75 (20.8% below fair value)
No single metric tells the full story. See the BKK:TNH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thai Nakarin Hospital PCL operates a general hospital in Thailand. It provides inpatient and outpatient services and medical services. The company's operating units consist of an emergency department, X-ray unit, pharmacy department, physical therapy department, laboratory department, and others.
87GF Score
Get the complete analysis for BKK:TNH
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:TNH has been successfully added to your 
